[A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation] - PubMed (original) (raw)
[Article in Chinese]
Shichun Lu 2, Menglong Wang, Jushan Wu, Dongdong Lin, Qingliang Guo, Wei Lai, Daobing Zeng, Chuanyun Li, Yuan Liu, Libo Sun, Dong Yan, Ning Li
Affiliations
- PMID: 24924566
Comparative Study
[A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation]
[Article in Chinese]
Xiaofei Zhao et al. Zhonghua Wai Ke Za Zhi. 2014 Apr.
Abstract
Objective: To evaluate the influence of sirolimus on the long-term survival of patients after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC).
Methods: Clinic data of 165 consecutive patients who underwent OLT for HCC from February 2005 to March 2012 was analyzed retrospectively. Among them, 94 patients were treated with a sirolimus-based immunosuppressive protocol after OLT, while the other 71 patients with a FK506-based protocol. Postoperative survival time, survival, disease-free survival (DFS) and tumor recurrence rates between the two groups were compared.
Results: The 2 groups were comparable in all clinicopathologic parameters. The sirolimus-based group had higher patient survival rates than the control group at 1-year (87% vs. 97%, P = 0.03), 2-year (80% vs. 88%), 3-year (76% vs. 85%) and 5-year (63% vs. 75%). The 1-year, 2-year, 3-year and 5-year recurrence rates were 12% vs. 3%, 17% vs. 9%, 21% vs. 9% (P = 0.04) and 31% vs. 16% (P = 0.03). Early and mid-HCC (I - II stage) of 131 cases (control group 61 cases, sirolimus-based group of 70 patients). The 1-year, 2-year, 3-year and 5-year survival rates were 90% vs. 97% , 80% vs. 90%, 78% vs. 86% and 65% vs. 82% (P = 0.04) and recurrence rates were 10% vs. 3%, 16% vs. 8%, 18% vs. 8% and 29% vs. 11% (P = 0.01).
Conclusion: The sirolimus-based immunosuppressive protocol reduce long-term postoperative recurrence rate and improve the survival rate of patients after OLT for HCC significantly (especially early-mid HCC).
Similar articles
- Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.
Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, Tang ZY, Fan J. Zhou J, et al. Transplant Proc. 2008 Dec;40(10):3548-53. doi: 10.1016/j.transproceed.2008.03.165. Transplant Proc. 2008. PMID: 19100435 - Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I. Zimmerman MA, et al. Liver Transpl. 2008 May;14(5):633-8. doi: 10.1002/lt.21420. Liver Transpl. 2008. PMID: 18324656 - Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Zhou J, Fan J, Wang Z, Wu ZQ, Qiu SJ, Huang XW, Yu Y, Sun J, Xiao YS, He YF, Wang YQ, Tang ZY. Zhou J, et al. World J Gastroenterol. 2006 May 21;12(19):3114-8. doi: 10.3748/wjg.v12.i19.3114. World J Gastroenterol. 2006. PMID: 16718799 Free PMC article. - Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.
Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW. Zimmerman MA, et al. Arch Surg. 2008 Feb;143(2):182-8; discussion 188. doi: 10.1001/archsurg.2007.39. Arch Surg. 2008. PMID: 18283144 Review. - Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E, Mamou C, RodrÃguez-Castro KI, Burra P. Cholongitas E, et al. Transpl Int. 2014 Oct;27(10):1039-49. doi: 10.1111/tri.12372. Epub 2014 Jul 18. Transpl Int. 2014. PMID: 24943720 Review.
Cited by
- Hepatocellular carcinoma: A comprehensive review.
Waller LP, Deshpande V, Pyrsopoulos N. Waller LP, et al. World J Hepatol. 2015 Nov 18;7(26):2648-63. doi: 10.4254/wjh.v7.i26.2648. World J Hepatol. 2015. PMID: 26609342 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical